Optimisation of a new class of inflammation-resolving GPCR agonists for the treatment of Heart Failure with preserved Ejection Fraction (HFpEF)
Fields of Study & Subjects
Receptor Mechanisms and Signaling
Heart Failure Treatment and Management
Adenosine and Purinergic Signaling
Publication details
- Journal / source
- Therapeutic Innovation Australia
- Publication date
- 17 February 2026
- Language
- EN